Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Background The Targeted Agent and Profiling Utilization Registry (TAPUR) Study, a phase II basket study, evaluates anti-tumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known as drug targets. Objective With no known genomic targ...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Targeted oncology 2020-12, Vol.15 (6), p.733-741
Hauptverfasser:	Fisher, Julie G., Tait, David, Garrett-Mayer, Elizabeth, Halabi, Susan, Mangat, Pam K., Schink, Julian C., Alvarez, Ricardo H., Veljovich, Dan, Cannon, Timothy L., Crilley, Pamela A., Pollock, Theodore, Calfa, Carmen J., Al Baghdadi, Tareq, Thota, Ramya, Fleming, Nicole, Cotta, Jared A., Rygiel, Andrew L., Warren, Sasha L., Schilsky, Richard L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antineoplastic Agents, Immunological - pharmacology Antineoplastic Agents, Immunological - therapeutic use Biomedicine Breast cancer Breast Neoplasms - drug therapy Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Ovarian Epithelial - drug therapy Cetuximab - pharmacology Cetuximab - therapeutic use Disease control Female Humans Immunotherapy Lung cancer Lung Neoplasms - drug therapy Male Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Mutation Oncology Original Research Article Ovarian cancer Proto-Oncogene Proteins B-raf - genetics Registries Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!